Immunovaccine jab protects monkeys from anthrax; Tekmira hep B RNAi drug shows promise;

> A University of Nebraska Medical Center researcher has received a 5-year, $3.3 million grant from NIH to study 10 rare diseases that affect children beginning in infancy or early childhood and throughout their life. Release

> Amgen ($AMGN) is looking into ways to ramp up production of ZMapp, an investigational drug developed by San Diego-based Mapp Biopharmaceutical to fight Ebola. More

> Immunovaccine unveiled positive results from a preclinical study, showing that its DepoVax delivery system prevented anthrax infections in monkeys exposed to the bacteria. Release

> Tekmira Pharmaceuticals ($TKMR) rolled out new preclinical data, showing that its RNA interference therapy TKM-HBV was effective in mice against hepatitis B. More

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.